An Orbimed-backed biotech launches with $85M and plans for a new kind of DNA medicine

An Orbimed-backed biotech launches with $85M and plans for a new kind of DNA medicine

Submitted by admin on October 24, 2023 - 9:59am
Source: 
BioPharma Dive
News Tags: 
Rampart Biosciences
OrbiMed
Alexion Pharmaceuticals
Strensiq
hypophosphatasia
Headline: 
An Orbimed-backed biotech launches with $85M and plans for a new kind of DNA medicine
snippet: 

Rampart Biosciences is working on an experimental treatment to compete with Alexion Pharmaceuticals’ Strensiq, which treats hypophosphatasia.

Do Not Allow Advertisers to Use My Personal information